Kadcyla has helped many women living with breast cancer, but NHS patients are set to be denied the drug because it is too expensive.
An NHS whistleblower told Daybreak if he had his time again he would not raise concerns about patient safety for fear of retribution.
The Tonight programme has taken a look at Britain's binge drinking culture and the impact it's having on the health of young people.
The British Heart Foundation (BHF) has called healthy eating on a budget "one of the biggest challenges of our times" after it found more than a third of people in the UK are struggling to eat healthily due to high food prices.
Victoria Taylor, senior dietitian at the BHF, said:
With the increasing cost of a weekly shopping basket it's a real concern that despite people's best intentions they're struggling to eat healthily.
But there are ways you can make healthy home-cooking more affordable, so that the rising price of your food shop doesn't need to come at a cost to your heart health.
More than a third of people in the UK are struggling to afford to eat healthily due to high food prices, a charity has warned.
A survey by the British Heart Foundation (BHF) suggests that two thirds of people in the UK would like to eat more healthily, but 42% said they cannot because it is too expensive.
Soaring food prices have seen grocery bills rise almost twice as fast as rent in the last five years, the BHF said, leaving nearly 40% of people admitting they have to sacrifice healthiness for cost when it comes to groceries.
The National Institute for Health and Care Excellence (NICE) faced "difficult decisions" when it deemed a breast cancer drug which can extend sufferers lives by "up to six months" was too expensive, according to a health expert.
Dr Hilary Jones told Daybreak the £90,000 price tag per patient would have meant taking funds away from other vital services the NHS provides.
The chief executive of health watchdog Nice has urged a drug manufacturer to look at cutting the cost of Kadcyla - a cancer treatment deemed 'too expensive' for routine NHS use.
Sir Andrew Dillon said he hoped Roche would "act in the best interest of patients" and use the consultation period to look again at their evidence and consider if there was "more" they could do to reduce the price of the treatment.
Jayson Dallas, general manager of the company, responded to Nice's announcement, saying: "Roche is extremely disappointed that Nice has failed to safeguard the interests of patients with this advanced stage of aggressive disease."
He added that he hoped the watchdog would "arrive at a sustainable solution that builds upon the success" of the Cancer Drugs Fund, so that "patients continue to have rapid access to much needed cancer medicines".
A new breast cancer drug which extends women's lives by almost six months could be blocked from routine NHS access because it is too expensive, a health watchdog says.
Kadcyla, manufactured by Roche, can cost more than £90,000 per patient and is not effective enough to justify the price the NHS is being asked to pay, the National Institute for Health and Care Excellence (Nice) said.
The watchdog, which decides which new medicines are cost effective, said its guidance for the drug, also known as trastuzumab emtansine, was in draft form and is now up for public consultation.
If the recommendations are adopted, patients would have to apply to their local NHS and to the Cancer Drugs Fund (CDF) for the drug, a Nice spokeswoman said.
At least 1,000 hospital patients in England die each month from avoidable kidney problems, according to a new study commissioned by the NHS.
Researchers found that acute kidney injury (AKI) causes between 15,000 and 40,000 excess deaths every year.
The condition refers to a loss of kidney function and can develop very quickly. It can occur in people who are already ill with conditions such as heart failure or diabetes, and those admitted to hospital with infections.
AKI can also develop after major surgery, such as some kinds of heart surgery, because the kidneys can be deprived of normal blood flow during the procedure.
AKI costs the health service over £1 billion every year and is responsible for nearly eight times as many deaths as superbug MRSA at its peak, according to a study commissioned by NHS Improving Quality.
Cancer Research UK says too much UV radiation from the sun or sunbeds can damage the DNA in skin cells. If the DNA builds up enough damage over time, it can cause cells to start growing out of control, leading to skin cancer.
There are two main types of UV rays. Both types can cause skin cancer - UVB and UVA.
Sunburn is a clear sign that the DNA in your skin cells has been damaged by too much UV radiation. Sunburn doesn’t have to be raw, peeling or blistering. If your skin has gone red in the sun, it’s burnt.
The above video, by Cancer Research UK, explains what happens to skin when it becomes sunburnt.
Cancer Research UK is warning people to be careful with sunbeds and sunny weather.
Who is the most at risk of skin cancer?
- Fair skin
- Moles or freckles
- Red or fair hair
- Light coloured eyes
- Family history of skin cancer
- History of sunburn
If you have naturally brown or black skin you are much less likely to develop skin cancer. This is because people with naturally brown or black skin have more melanin pigment in their cells. This helps protect the skin from damaging UV rays.
The number of people diagnosed with skin cancer in Yorkshire has doubled in the last 20 years. Around a thousand people in our region are now developing the disease every year.
Amanda Crosland from Leeds was diagnosed with malignant melanoma in 2001. Being red-haired and fair skinned, the mum to two daughters has always covered up in the sun. So, when she noticed a new mole, she got it checked out straight away.